Risk communication workshop
This article was originally published in The Gray Sheet
FDA will hold a public meeting in cooperation with AdvaMed Sept. 26 in North Bethesda, Md., to discuss how the device industry and government communicate product risk to doctors, patients and the public, and ways in which this process could be improved. The agency will present results from its recent research on the topic...
You may also be interested in...
As the MHRA prepares to grant approval to the Oxford/AstraZeneca vaccine, Wockhardt is set to supply 100 million doses for the UK government’s own use and its WHO commitments. The company is also in talks with global vaccine developers to manufacture their COVID-19 vaccines for emerging economies
A combined final opinion on the European Chemicals Agency’s proposed microplastic restriction is expected from ECHA committees by year-end, at which point the European Commission will consider whether and when microplastic must be removed from all leave-on cosmetic products marketed in the EU.